Sodaro, Gaetano
(2017)
THE REGULATORY ROLE OF THE TRANSCRIPTION FACTOR ZNF224 IN CHRONIC MYELOGENOUS LEUKEMIA.
[Tesi di dottorato]
| Tipologia del documento: |
Tesi di dottorato
|
| Lingua: |
English |
| Titolo: |
THE REGULATORY ROLE OF THE TRANSCRIPTION FACTOR ZNF224 IN CHRONIC MYELOGENOUS LEUKEMIA |
| Autori: |
| Autore | Email |
|---|
| Sodaro, Gaetano | gaetano.sodaro@unina.it |
|
| Data: |
8 Aprile 2017 |
| Numero di pagine: |
70 |
| Istituzione: |
Università degli Studi di Napoli Federico II |
| Dipartimento: |
Medicina Molecolare e Biotecnologie Mediche |
| Dottorato: |
Medicina molecolare e biotecnologie mediche |
| Ciclo di dottorato: |
29 |
| Coordinatore del Corso di dottorato: |
| nome | email |
|---|
| Avvedimento, Vittorio Enrico | vittorioenrico.avvedimento@unina.it |
|
| Tutor: |
| nome | email |
|---|
| Costanzo, Paola | [non definito] |
|
| Data: |
8 Aprile 2017 |
| Numero di pagine: |
70 |
| Parole chiave: |
ZNF224; CHRONIC MYELOGENOUS LEUKEMIA; IMATINIB; IMTATINIB-RESISTANCE; C-MYC; AXL; TRANSCRIPTIONAL REPRESSION; AG490; APOPTOSIS; |
| Settori scientifico-disciplinari del MIUR: |
Area 05 - Scienze biologiche > BIO/10 - Biochimica
Area 05 - Scienze biologiche > BIO/11 - Biologia molecolare |
[error in script]
[error in script]
| Depositato il: |
02 Mag 2017 14:03 |
| Ultima modifica: |
13 Mar 2018 11:27 |
| URI: |
http://www.fedoa.unina.it/id/eprint/11646 |
| DOI: |
10.6093/UNINA/FEDOA/11646 |
Abstract
The transcription factor ZNF224 was recently identified as a proapoptotic factor in chronic myelogenous leukemia (CML), mediating ara-C drug- induced apoptosis. Most recently, we demonstrated that the fusion protein Bcr-Abl negatively regulates ZNF224 expression in CML, while Bcr-Abl inhibition by the tyrosine kinase inhibitor (TKI) Imatinib, used as first-line treatment in CML, triggers ZNF224 up-regulation in CML cells.
On the other hand, Bcr-Abl via Jak2 activation increases the expression of c-Myc gene, which is required for Bcr-Abl oncogenic transformation in CML. Coherently, Bcr-Abl inhibition by Imatinib results in c-Myc reduction, which represents a key step for Imatinib and new generation TKIs responsiveness in CML.
In this work, we demonstrated that ZNF224 is a novel transcriptional repressor of c-Myc oncogene in CML and coherently, hampers c-Myc proliferative network, reducing CML cells proliferation and DNA synthesis. Intriguingly, our data describe a crucial role for ZNF224 induction in Imatinib repression on c-Myc in CML and subsequently demonstrate that alterations in ZNF224 binding sites on c-Myc promoter significantly affect Imatinib transcriptional repression of c-Myc gene in CML cells, thus suggesting a potential implication of this region in Imatinib responsiveness. In addition, we further reveal that AG490, a potent Jak2 inhibitor, negatively regulate c-Myc, at least in part via ZNF224 up-regulation.
A crucial problem linked to TKIs treatment in CML is the possibility to develop resistance towards these drugs. Here we demonstrate that ZNF224 expression is lower in Imatinib-resistant CML cells and that its induction by Imatinib is impaired, but can be restored by AG490. Consistently, AG490 treatment or ZNF224 induction in Imatinib-resistant CML cells results in c- Myc reduction and apoptosis induction.
Moreover, enforcing ZNF224 implications in Imatinib responsiveness, we further demonstrate that ZNF224 is a transcriptional repressor of AXL tyrosine kinase in CML, which plays a crucial role in Imatinib resistance in CML.
Taken together, our results identify new mechanisms by which ZNF224 transcription factor exerts an anti-oncogenic effect in CML and highlight the crucial role of ZNF224 in Imatinib responsiveness, thus providing convincing evidence that ZNF224 induction could play a role in overcoming Imatinib resistance in CML cells.
Downloads per month over past year
Actions (login required)
 |
Modifica documento |
